News and Announcements
Imugene Ltd (ASX: IMU) Seeking Capital for HER-Vaxx
- Published November 21, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Imugene Ltd (ASX: IMU) is raising capital for further immuno-oncology clinical testing
- HER-Vaxx, an anti-cancer vaccine therapy, has been utilised in initial clinical testing on patients with gastric cancer.
- The ASX has granted a halt on trade allowing the company to prepare.
Imugene Ltd (ASX: IMU), a clinical-stage immuno-oncology company treating gastric, breast, ovarian, lung & pancreatic cancers, has arranged a halt on trade approved by the Australian Stock Exchange.
This halt comes about as a result of the company’s desire to raise capital. The halt will allow Imguene to have sufficient preparation time.
HER-Vaxx, the leading Imugene product that capitalises on the body’s ability to create antibodies against disease, has commenced clinical testing on gastric cancer patients.
Two leading antibody medications apply the same method as HER-Vaxx employs, utilising the same receptor. These alternative products possessing annual sales of US $8.2 billion.
About Imugene Ltd (ASX: IMU)
Imugene is a clinical stage immuno-oncology company. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
